Objective: Literature is quite poor about the clinical effects of novel psychoactive substances (NPS) and the long-term consequences of NPS use in psychiatric patients. Consequently, it is of the greatest interest to examine which effects NPS can exert in patients with previous severe mental illness (SMI), such as psychotic patients. The aim of this work was a comprehensive review about NPS use in patients with SMI.
| INTRODUCTION
The European Union defined a "novel psychoactive substance" as a new narcotic or psychotropic drug, either in pure form or in a preparation, that is not scheduled under the Single Convention on Narcotic Drugs of 1961 or the Convention on Psychotropic Substances of 1971, but which may pose a public health threat comparable to substances listed in the aforementioned conventions (Martinotti et al., 2014) . Novel psychoactive substances (NPS) are a wide and heterogeneous group of substances, often pharmacological analogs of prohibited compounds. They are also known as "legal high," "bath salts," "research chemicals," or, in a broader sense, "designer drugs." Actually, there has been growing clinical, public, and media awareness and concern about their availability and potential harmfulness (Baumeister, Tojo, & Derek, 2015) .
The ability of NPS to induce a very wide range of mental state modifications is well known, as well as to cause transitory psychotic states or even long-lasting psychiatric disorders, so to become a factor of growing importance for public health. NPS show variable and specific mechanisms of action, potentially interfering with neurobiology of several psychiatric disorders. According to a recent extensive review by Schifano, Orsolini, Duccio Papanti, and Corkery (2015) , mechanism of action and main mental consequences of NPS consumption in healthy subjects are presented in Table 1 . Mechanisms of action are very wide and heterogeneous, ranging among different 5-HT receptors' agonism and antagonism, dopamine or noradrenaline increase, CB1 receptor agonism, and so forth.
The phenomenon may be of great clinical relevance, considering that many psychiatric patients consume psychotropic drugs, both "traditional" like cannabis and of the NPS family. Very poor epidemiological data are available at regard; Martinotti et al. (2014) presented results obtained in Italian healthy and psychiatric populations ( Table 2) , showing 14.1% of use of NPS in psychiatric patients, compared to 29.3% of cannabis and 4.6% of cocaine consumers. The NPS use is higher in depressed (15.6%) and bipolar (14.8%) patients. Despite this, little is known about the effects of NPS and the long-term consequences of NPS use on the mental state of psychiatric patients. Literature is quite poor on the topic, only limited to single cases or small patients' sample description. In this contest, the purpose of this survey was to conduct a systematic review about the clinical consequences of the use of NPS in patients with severe mental illness (SMI; psychotic disorders and bipolar disorder patients), aiming at obtaining information about the clinical outcome of their interaction with the previous psychopathology state of the patients and at identifying some possible specific clinical features associated with their consumption.
| METHODS
We searched Medline or PubMed for relevant English-language citations and reviews describing relationships between NPS use and mental disorders. We used the terms "new psychoactive substances," "novel psychoactive substances," and "new substances in mental illness or psychiatric disorders." A similar search was carried out for the main groups of substances and associated psychiatric manifestations. The search strategies did not provide any limits to the dates of the considered papers. All the papers regarding clinical cases or surveys on the topic of NPS use consequences in severe psychiatric patients were included in the review. Exclusion criteria considered only a qualitative evaluation of the considered articles. The clinical field of interest was defined as that of patients affected by SMI, because the one previous review used this definition to describe the clinical area considered. All the included papers reported cases of patients affected by psychotic disorders and bipolar disorders, so that these are the diagnostic categories for which the term of SMI was used.
| RESULTS
The results of this systematic review provided few results about the clinical consequences of NPS use in patients previously affected by severe psychiatric disorders. The one existing survey of the literature is by Gray, Bressington, Hughes, and Ivanecka (2016) , who realized a systematic review about the effects of NPS in patients with SMI. This survey considered clinical cases from 12 case reports, one crosssectional survey, and one qualitative study, with patients aged between 20 and 35 years. Interestingly, the survey reported NPS use in psychiatric patients from different countries (Table 3) . providing putative information about regional differences in substances' diffusion.
The main clinical consequences in the mental state of the patients are reported in Tables 4-6 Some clinical considerations can be made regarding the cases presented in the Gray's review. Boucher, Hernu, and Citterio-Quentin (2015) have shown that
NBOMe use in a patient with schizophrenia caused abnormalities in the executive functions. This is an interesting report about the cognitive effect of the substance, even if it is not well specified in the paper the preceding degree of cognitive impairment in the patient.
Celofiga, Koprivsek, and Klavz (2014) Some information is provided also on NPS effect with respect to resistance to pharmacological treatment, with reported psychotic symptoms persisting for 4 weeks despite olanzapine treatment in a patient with schizophrenia after "bath salts" consumption (McClean et al., 2012) , associated with bizarre behavior, suicidality, visual, tactile, and auditory hallucinations (Thornton, Gerona, & Tomaszewski, 2012) .
In Gray's review, NPS use is suggested to cause resistance to previously effective treatments, particularly with respect to NPS-induced aggression, in patients with SMI, with negative influence on doses or types of requested medical treatment.
| DISCUSSION
Consumption of traditional substances of abuse (alcohol, cannabis, opioids, and cocaine) (Martinotti et al., 2014) is often in comorbidity with other psychiatric disorders (Merikangas, Herrell, Swendsen, Rössler, Ajdacic-Gross, & Angst, 2008; Toftdahl, Nordentoft, & Hjorthøj, 2016) .
Beyond "classic" substances of abuse, it is recognized for NPS a growing importance for public health. As seen, NPS are a wide and heterogeneous group of new narcotic or psychotropic drugs (Martinotti et al., 2014) , classified into at least six main classes (phenethylamines, synthetic cannabinoids, synthetic cathinones, tryptamines, piperazines, and others; Schifano et al., 2015) . Potential NPS consumers are found also among psychiatric patients, especially, in Italian population, in depressed (Soyka, 2000) .
The limit of all the aforementioned observations is that they focused just on reporting the acute effects of NPS and that they have analyzed just small patients' sample, often single cases (Boucher et al., 2015; Falgiani et al., 2012; Fröhlich, Lambe, & O'Dea, 2011; Khanra et al., 2015; McClean et al., 2012; Thornton et al., 2012) , four cases (Celofiga et al., 2014) , or five cases (Imam et al., 2013) . In addition, the small samples were not sex homogeneous, formed either by males (for example, Fröhlich et al., 2011; Imam et al., 2013) or females (Falgiani et al., 2012) .
As a general remark according to the poor and really scarce existing literature, NPS may exert some relatively severe effects on people with SMI. Their use appears in fact related to severe dissociative states and confusion in psychotics, behavior changes (acute anxiety with agitation and aggressive or extremely aggressive behavior), cognitive decline, frequent need of restraint, relapse or worsening of a preexistent psychosis or preexistent bipolar disorder (Schifano et al., 2015) , persistent worsening of psychotic or manic-like symptoms course, or onset of new severe symptom (65%; Celofiga et al., 2014; Every-Palmer, 2011; Lally et al., 2013) .
What is still unclear and must be better addressed in future studies is whether in SMI, they simply worsen preexistent psychotic states in 
| LIMITS
The results of the survey have several limits. First, NPS group includes an increasing number of both known and newly emerging substances, with several and multiple mechanisms of action, whose pharmacodynamic properties are not fully well known. These aspects play a crucial role because they make difficult to identify neurobiological effects in longterm users, often consuming different substances associated or over time.
This is certainly even more relevant in subjects affected by SMI.
A second limit is linked to the absolute lack of control of NPS consumption. NPS use is illegal, and these kind of substances are occupying an increasingly predominant position on the illicit market of drugs. There are not therefore sufficient methods or specific test to identify all NPS in users. They more frequently access to emergency departments because of symptoms that are not specific, often similar to those due to different substances intoxication.
Objective data to determine the effective consumption are completely not sufficient, and any retrospective study is impossible to be usefully carried out.
As a third limit, there are few studies about NPS use in patients with SMI and, as seen, limited to case studies. Large samples are very difficult to be collected, due to the number and extreme heterogeneity of the substances potentially implicated, as well as to the fact that they are mostly illicit and information on consumption is just very seldom and incompletely given by consumers. Moreover, the consumers are themselves often unaware about the really taken substances, and their preexistent mental disorder may further reduce their ability of comprehension and of awareness of their own behavior.
Otherwise, ethical reasons make obviously quite impossible any type of regular controlled study. The available information is so limited to single cases or small groups of patients, and no clinical conclusions can be generalizable with the wider populations of people affected by different forms of SMI and using different and mostly unknown types of NPS.
| CONCLUSIONS
The NPS use in patients with SMI is a frequent phenomenon, probably still underestimated. NPS potentially have serious effects on people with SMI. The most commonly reported effects of NPS were psychotic symptoms and significant changes in behavior. Otherwise, the scarce observations determine that more evidences are needed to establish the causal and effective connection between NPS use and course of illness, type of psychiatric symptoms, and treatment outcome in terms of adherence or response. Therefore, careful and constant monitoring and accurate clinical evaluation will be necessary to search a real connection between NPS use and course and clinical phenomenology of an SMI.
